Cochlear builds in China, develops new implant

Bionic ear manufacturer Cochlear (ASX: COH) is pressing ahead building a new factory in China and moving to human trials of a breakthrough new fully implantable cochlear device. Chairman Rick Holliday-Smith told Cochlear’s annual general meeting that ‘sound’ progress had been made developing its new Chinese manufacturing facility in Chengdu (pictured). He said the project…

Noxopharm reports anti-cancer effects of Veyonda

Sydney anti-cancer treatment company Noxopharm (ASX: NOX) has reported anti-cancer effects of its Veyonda treatment in a small group of patients suffering advanced prostate cancer. The 14 patients’ cancers were metastatic and they had exhausted all treatment options when given Veyonda in association with low-dosage radiation in a single lesion. After six months, cancer progression…